https://www.scribd.com/document/622985677/HYPR-Patent
REGENXBIO Presents Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting
Suprachoroidal delivery of RGX-314 well tolerated in 50 patients in Cohorts 1-3 with no drug-related serious adverse events
Positive initial data from Cohort 1 at six months after one-time treatment of
